Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
Business
Henry Saker-Clark

AstraZeneca share prices drop amid £300bn mega-merger talks with US rival

Reports suggest AstraZeneca has engaged in discussions with its US counterpart, Bristol Myers Squibb, regarding a potential merger that could establish a pharmaceutical behemoth valued at over £300 billion.

The Financial Times indicated that these talks between the two drugmakers have been ongoing in recent months.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.